Peptides DB
Research-centric peptide and protocol reference hub
Study 19 of 19Lanreotide literatureKidney international reports · Observational · Phase 42026

Fibrogenesis Biomarkers and Clinical Disease Progression in ADPKD.

Urinary collagen fragments uPRO-C3/Cr and uPRO-C6/Cr are associated with kidney outcomes in ADPKD, but their clinical utility remains to be fully established.

Read at Kidney international reportsAdd to compare

Where it sits

this study against the rest of the lanreotide corpus
0
Preclinical
14
Observational · this one
1
Open-label
3
Randomised
1
Reviews

Summary and findings

This study evaluated the association of collagen fragments with clinical outcomes in 302 patients with autosomal dominant polycystic kidney disease (ADPKD) over a mean follow-up of 2.4 years. The findings indicated that uPRO-C3/Cr and uPRO-C6/Cr were independently associated with kidney outcomes. No therapeutic claims are made regarding lanreotide or other treatments.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m² per year.n=302Phase 42026

Abstract

The authors’ words, as Kidney international reports supplied them

<h4>Introduction</h4>Fibrogenesis contributes to disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD). In this exploratory study, we evaluated the association of protease-generated circulating and urinary collagen fragments (type III collagen degradation [C3M], type III collagen formation [PRO-C3], and type VI collagen formation [PRO-C6]), reflecting fibrogenesis and fibrolysis, with clinical outcomes in ADPKD.<h4>Methods</h4>We included 302 patients from the DIPAK-1 trial (lanreotide vs. standard treatment), with a mean baseline age of 48.9 ± 7.3 years and estimated glomerular filtration rate (eGFR) of 51.3 ± 11.5 ml/min per 1.73 m<sup>2</sup>. Kidney endpoints were eGFR slope, rapid disease progression (eGFR loss ≥3 ml/min per 1.73 m<sup>2</sup> per year), and a composite kidney endpoint (30% eGFR loss or initiation of kidney replacement therapy). Net benefit analysis was performed to assess clinical utility.<h4>Results</h4>During 2.4 ± 0.4 years of follow-up, mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m<sup>2</sup> per year, 190 patients (62.9%) had rapid disease progression, and 87 (28.8%) reached the composite endpoint. After adjustment for sex, baseline age, baseline eGFR, Mayo imaging class (MIC), <i>PKD</i> pathogenic variant and treatment group, uPRO-C3/Cr and uPRO-C6/Cr were independently associated with eGFR slope, rapid disease progression, and the composite endpoint. uPRO-C3/Cr was also associated with HtTKV growth rate. Adding uPRO-C3/Cr or uPRO-C6/Cr improved prediction of rapid disease progression, increasing area under curve (AUC) from 0.78 (95% confidence interval [CI], 0.73-0.86) to 0.79 (95% CI, 0.73-0.86) and 0.80 (95% CI, 0.73-0.86), respectively. Decision curve analysis did not show a meaningful net benefit.<h4>Conclusion</h4>These findings demonstrate that uPRO-C3/Cr and uPRO-C6/Cr were independently associated with kidney outcomes in ADPKD, providing clinical evidence that extracellular matrix (ECM) remodeling is associated with ADPKD disease progression.

Background

This paper addresses the role of fibrogenesis in the progression of autosomal dominant polycystic kidney disease (ADPKD). Prior studies have indicated that extracellular matrix remodeling may be linked to kidney disease progression, but specific biomarkers for this process have not been thoroughly investigated. This study is significant as it explores the association between collagen fragments and clinical outcomes in a population of ADPKD patients.

Methods

The study included 302 patients from the DIPAK-1 trial, with a mean age of 48.9 ± 7.3 years and an estimated glomerular filtration rate (eGFR) of 51.3 ± 11.5 ml/min per 1.73 m². The primary outcomes were eGFR slope, rapid disease progression (defined as eGFR loss ≥3 ml/min per 1.73 m² per year), and a composite kidney endpoint (30% eGFR loss or initiation of kidney replacement therapy). The follow-up duration was 2.4 ± 0.4 years.

Results

The mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m² per year. Of the patients, 62.9% experienced rapid disease progression, and 28.8% reached the composite endpoint. After adjustments for various factors, urinary collagen fragments uPRO-C3/Cr and uPRO-C6/Cr were found to be independently associated with eGFR slope and rapid disease progression. The addition of these markers improved the area under the curve (AUC) for predicting rapid disease progression.

Interpretation

The findings suggest that urinary collagen fragments may serve as biomarkers for disease progression in ADPKD, aligning with previous literature on the role of extracellular matrix remodeling. However, while the statistical significance of the associations is noted, the clinical relevance remains uncertain due to the lack of a meaningful net benefit demonstrated in decision curve analysis. The study's exploratory nature and potential confounding factors limit the strength of the conclusions.

Key findings

  • Mean eGFR slope was -4.02 ± 3.64 ml/min per 1.73 m² per year.
  • 190 patients (62.9%) had rapid disease progression (eGFR loss ≥3 ml/min per 1.73 m² per year).
  • 87 patients (28.8%) reached the composite endpoint of 30% eGFR loss or initiation of kidney replacement therapy.
  • AUC for prediction of rapid disease progression increased from 0.78 (95% CI, 0.73-0.86) to 0.79 (95% CI, 0.73-0.86) with uPRO-C3/Cr.
  • AUC for prediction of rapid disease progression increased to 0.80 (95% CI, 0.73-0.86) with uPRO-C6/Cr.

Limitations

  • Exploratory study design.
  • Decision curve analysis did not show a meaningful net benefit.
  • Potential confounding factors not fully addressed.
  • Follow-up duration of 2.4 years may be insufficient for long-term outcomes.

Elsewhere in the Lanreotide corpus

BIntravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.Nature medicine · 2026HumanBWhen Thyrotropin Meets Growth Hormone: Clinical Challenges of a Mixed GH/TSH-Secreting PIT1-Lineage Pituitary Neuroendocrine Tumorbiorxiv-preprint · 2026 · IGF-1 decreased from 1128 ng/mL to 846 ng/mL after lanreotide treatment.HumanARandomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.Human vaccines & immunotherapeutics · 2026 · SCR: 84.9% (Rotarix PCV‑free) vs 88.7% (Rotarix); difference -3.73% (95% CI -6.93, -0.55; p = .0317)HumanAOrforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026 · Cohort 1 maintained an MBE of 74.7% body weight reduction with orforglipron vs 49.2% with placebo at week 52, P<0.001.HumanBNeuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasmbiorxiv-preprint · 2023 · Serum CgA reduced from 3636 to <100 ng/mL after five months.HumanBPatient Point of View of the diagnosis, treatment and follow up in acromegaly: Single center study from a tertiary centerbiorxiv-preprint · 2024 · Overall disease control achieved in 38 patients (65.5%).Human